Soleno Therapeutics (SLNO) Other Non-Current Liabilities (2016 - 2019)
Historic Other Non-Current Liabilities for Soleno Therapeutics (SLNO) over the last 7 years, with Q3 2019 value amounting to $6.1 million.
- Soleno Therapeutics' Other Non-Current Liabilities rose 696.53% to $6.1 million in Q3 2019 from the same period last year, while for Sep 2019 it was $6.1 million, marking a year-over-year increase of 696.53%. This contributed to the annual value of $5.6 million for FY2018, which is 1115.7% up from last year.
- According to the latest figures from Q3 2019, Soleno Therapeutics' Other Non-Current Liabilities is $6.1 million, which was up 696.53% from $6.0 million recorded in Q2 2019.
- Soleno Therapeutics' Other Non-Current Liabilities' 5-year high stood at $20.3 million during Q1 2015, with a 5-year trough of $61739.0 in Q4 2016.
- Moreover, its 5-year median value for Other Non-Current Liabilities was $1.1 million (2017), whereas its average is $4.0 million.
- As far as peak fluctuations go, Soleno Therapeutics' Other Non-Current Liabilities crashed by 9725.27% in 2016, and later surged by 813142.58% in 2017.
- Soleno Therapeutics' Other Non-Current Liabilities (Quarter) stood at $109404.0 in 2015, then plummeted by 43.57% to $61739.0 in 2016, then skyrocketed by 8131.43% to $5.1 million in 2017, then rose by 11.16% to $5.6 million in 2018, then rose by 7.38% to $6.1 million in 2019.
- Its Other Non-Current Liabilities stands at $6.1 million for Q3 2019, versus $6.0 million for Q2 2019 and $5.9 million for Q1 2019.